Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: Evidence from latent class analysis.

被引：0
|
作者：
Vass, Caroline
Pinto, Cathy Anne
Myers, Kelley
Imai, Kentaro
Bussberg, Cooper
Bhattacharya, Rituparna
Calhoun, Shawna R.
Poulos, Christine
机构：
[1] RTI Hlth Solut, Manchester, England
[2] Merck & Co Inc, Rahway, NJ USA
[3] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HETEROGENEITY OF PATIENT PREFERENCES FOR LOW-DOSE ASPIRIN TREATMENT - EVIDENCE FROM A DISCRETE CHOICE EXPERIMENT IN ITALY
    Tervonen, T.
    Vora, P.
    Seo, J.
    Krucien, N.
    Marsh, K.
    Wessinger-Grafenhahn, U.
    Soriano, Gabarro M.
    VALUE IN HEALTH, 2020, 23 : S618 - S618
  • [32] Understanding patient and provider preferences in management of metastatic renal cell carcinoma (mRCC)
    Yazdanpanah, Omid
    Benjamin, David Joseph
    Vosoughi, Elham
    Raad, Ali
    Popal, Medina
    Kongtim, Piyanuch
    Mar, Nataliya
    Rezazadeh, Arash
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment
    Ornstein, Moshe C.
    Rosenblatt, Lisa C.
    Yin, Xin
    Del Tejo, Viviana
    Guttenplan, Sarah B.
    Ejzykowicz, Flavia
    Beusterien, Kathleen
    Will, Oliver
    Mackie, deMauri S.
    Skiles, Grace
    DeCongelio, Marc
    PATIENT PREFERENCE AND ADHERENCE, 2024, 18 : 1729 - 1739
  • [34] HETEROGENEOUS PREFERENCES IN THE ADJUNCT DRUG TREATMENT OF SEVERE HYPERCHOLESTEROLEMIA: A LATENT-CLASS ANALYSIS
    Muhlbacher, A. C.
    Sadler, A.
    Dippel, F.
    Juhnke, C.
    VALUE IN HEALTH, 2017, 20 (09) : A622 - A622
  • [35] Heterogeneity of provider preferences for HIV Care Coordination Program features: latent class analysis of a discrete choice experiment
    Fong, Chunki
    Conte, Madellena
    Zimba, Rebecca
    Carmona, Jennifer
    Gambone, Gina
    Baim-Lance, Abigail
    Robertson, McKaylee
    Irvine, Mary
    Nash, Denis
    HIV RESEARCH & CLINICAL PRACTICE, 2024, 25 (01)
  • [36] Bone metastases from renal cell carcinoma: patient survival after surgical treatment
    Fottner, Andreas
    Szalantzy, Melinda
    Wirthmann, Lilly
    Staehler, Michael
    Baur-Melnyk, Andrea
    Jansson, Volkmar
    Duerr, Hans Roland
    BMC MUSCULOSKELETAL DISORDERS, 2010, 11
  • [37] Bone metastases from renal cell carcinoma: patient survival after surgical treatment
    Andreas Fottner
    Melinda Szalantzy
    Lilly Wirthmann
    Michael Stähler
    Andrea Baur-Melnyk
    Volkmar Jansson
    Hans Roland Dürr
    BMC Musculoskeletal Disorders, 11
  • [38] Gender impact on renal cell carcinoma survival: A population-based analysis.
    Baidoun, Firas
    Ruhban, Inas A.
    Saad, Anas M.
    Gad, Mohamed
    Al-Husseini, Muneer J.
    Ornstein, Moshe Chaim
    Gupta, Shilpa
    Rini, Brian, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
    Rodenburg, R. J.
    Eskens, F. A. L. M.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2019, 12 : 137 - 141
  • [40] Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
    Narayan, Vivek
    Haas, Naomi Balzer
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2016, 9 : 65 - 72
12345